Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basket of Baskets modular phase II trial of molecularly matched targeted agents in advanced solid tumors
2024-514238-19-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of atezolizumab, amivantamab and futibatinib in Nonhematologic neoplasms (3 arms), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Overall response rate and Overall response rate at 12 weeks in prostate cancer arm 1G. Planned start Oct 2024; status: authorised.
02
Drugs
atezolizumabamivantamabfutibatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-514238-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514238-19-00.